Key Takeaways MRK is focused on Winrevair's growth as Keytruda, its top revenue driver, faces patent expiration in 2028. Winrevair showed significant efficacy in PAH phase III trials, leading to early study stoppages. The FDA granted priority review to MRK's sBLA to update Winrevair's label, with a decision due on Oct. 25.Merck’s (MRK) blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest revenue driver. The drug alone accounts for around 50% of ...

United Therapeutics (UTHR) reported $794.4 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 17.2%. EPS of $6.63 for the same period compares to $6.17 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $726.19 million, representing a surprise of +9.39%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being $6.29.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

Safe Harbor Statement All statements in this presentation are made as of April 30, 2025. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our revenue growth expec ...